These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 25658613)

  • 1. Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy.
    Odegard JM; Kelley-Clarke B; Tareen SU; Campbell DJ; Flynn PA; Nicolai CJ; Slough MM; Vin CD; McGowan PJ; Nelson LT; Ter Meulen J; Dubensky TW; Robbins SH
    J Immunother; 2015; 38(2):41-53. PubMed ID: 25658613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells.
    Tareen SU; Kelley-Clarke B; Nicolai CJ; Cassiano LA; Nelson LT; Slough MM; Vin CD; Odegard JM; Sloan DD; Van Hoeven N; Allen JM; Dubensky TW; Robbins SH
    Mol Ther; 2014 Mar; 22(3):575-587. PubMed ID: 24419083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered lentivector targeting of dendritic cells for in vivo immunization.
    Yang L; Yang H; Rideout K; Cho T; Joo KI; Ziegler L; Elliot A; Walls A; Yu D; Baltimore D; Wang P
    Nat Biotechnol; 2008 Mar; 26(3):326-34. PubMed ID: 18297056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrase-defective lentiviral vectors encoding cytokines induce differentiation of human dendritic cells and stimulate multivalent immune responses in vitro and in vivo.
    Daenthanasanmak A; Salguero G; Borchers S; Figueiredo C; Jacobs R; Sundarasetty BS; Schneider A; Schambach A; Eiz-Vesper B; Blasczyk R; Weissinger EM; Ganser A; Stripecke R
    Vaccine; 2012 Jul; 30(34):5118-31. PubMed ID: 22691433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
    Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
    Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the antigen encoded by adenoviral vectors to the DEC205 receptor modulates the cellular and humoral immune response.
    Tenbusch M; Nchinda G; Storcksdieck genannt Bonsmann M; Temchura V; Überla K
    Int Immunol; 2013 Apr; 25(4):247-58. PubMed ID: 23184617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines.
    Koya RC; Kimura T; Ribas A; Rozengurt N; Lawson GW; Faure-Kumar E; Wang HJ; Herschman H; Kasahara N; Stripecke R
    Mol Ther; 2007 May; 15(5):971-80. PubMed ID: 17375074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.
    Goold HD; Escors D; Conlan TJ; Chakraverty R; Bennett CL
    J Immunol; 2011 Apr; 186(8):4565-72. PubMed ID: 21389256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity.
    Hesse C; Ginter W; Förg T; Mayer CT; Baru AM; Arnold-Schrauf C; Unger WW; Kalay H; van Kooyk Y; Berod L; Sparwasser T
    Eur J Immunol; 2013 Oct; 43(10):2543-53. PubMed ID: 23784881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity.
    Song W; Kong HL; Carpenter H; Torii H; Granstein R; Rafii S; Moore MA; Crystal RG
    J Exp Med; 1997 Oct; 186(8):1247-56. PubMed ID: 9334364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
    Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
    Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An engineered novel lentivector specifically transducing dendritic cells and eliciting robust HBV-specific CTL response by upregulating autophagy in T cells.
    Ma S; Chen X; Tan Q; Li D; Dai S; Wu S; Yu Y; Zang G; Tang Z
    Cell Cycle; 2018; 17(10):1220-1234. PubMed ID: 30019620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2.
    Mossoba ME; Walia JS; Rasaiah VI; Buxhoeveden N; Head R; Ying C; Foley JE; Bramson JL; Fowler DH; Medin JA
    Mol Ther; 2008 Mar; 16(3):607-17. PubMed ID: 18180774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models.
    Kretz-Rommel A; Qin F; Dakappagari N; Torensma R; Faas S; Wu D; Bowdish KS
    J Immunother; 2007 Oct; 30(7):715-26. PubMed ID: 17893564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.
    Bryson PD; Han X; Truong N; Wang P
    Vaccine; 2017 Oct; 35(43):5842-5849. PubMed ID: 28916248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
    Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors.
    Dullaers M; Van Meirvenne S; Heirman C; Straetman L; Bonehill A; Aerts JL; Thielemans K; Breckpot K
    Gene Ther; 2006 Apr; 13(7):630-40. PubMed ID: 16355115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
    Immunology; 2006 Aug; 118(4):483-96. PubMed ID: 16895556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.